SOUND Pivotal Trial - (Sonomotion stOne comminUtion resoNance ultrasounD)

Urolithiasis Clinical Trial

— SOUND  

Official title:

Pivotal Study of the SonoMotion Break Wave™ (Trade Mark) System for the Comminution of Urinary Tract Stones

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05701098
• Other study ID #: CP0002
• Status: Recruiting
• Phase: N/A
• Start date: October 9, 2023
• Est. completion date: January 2025

Study information

• Verified date: February 2024
• Source: SonoMotion
• Contact: Emily Hergenreter
• Phone: 9255949600
• Email: emily.hergenreter[@]sonomotion.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to test the Break Wave™ system in patients with upper urinary tract stones. The main question it aims to answer is whether the device is safe and effective in fragmenting (breaking) stones.

Participants will a) undergo the Break Wave™ procedure, b) have a telehealth visit at 2 weeks, and c) return for an imaging study at approximately 10 weeks post-procedure.

Description:

This is a prospective, open-label, multi-center, single-arm (non-randomized) study to demonstrate the safety and effectiveness of breaking stones in the upper urinary tract using the SonoMotion Break Wave™ technology. Up to 116 patients will be screened to participate. Depending on the institution, the procedure may be performed in an outpatient hospital surgical environment, or in a non-surgical environment such as a clinic or office procedure room. Subjects will have a target stone diagnosed to be >4millimeter (mm) to 10 mm in size.

Safety will be measured by the adverse event occurrence, unplanned emergency department or clinic visits, and the need for further intervention. Effectiveness will be determined by the size of fragments identified at the 10 week follow-up imaging.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 116
• Est. completion date: January 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subjects presenting with at least one stone apparent on radiographic imaging.

2. Target stone must be within the upper urinary tract.

3. Target stone is indicated for shock wave lithotripsy (SWL) treatment per American Urological Association (AUA) 2016 guidelines.

4. Target stone size is > 4 mm and = 10 mm.

5. Subject is willing and able to provide informed consent and comply with the study protocol required follow up visits.

6. Target stone can be individually visualized from other stones.

Exclusion Criteria:

1. Subject has an acute untreated urinary tract infection or urosepsis.

2. Subject has an uncorrected bleeding disorder or coagulation abnormality.

3. Subject is confirmed to be or suspected to be pregnant.

4. Subject has a urinary tract obstruction distal to the stone.

5. Subject is receiving anticoagulants and is unable or not willing to cease the medication for the Break Wave procedure

6. Subject has stones that are not echogenically visible with ultrasound.

7. Subject belongs to a vulnerable group (prisoner, etc.).

8. Patients unwilling to comply with the follow-up protocol, including post-procedure radiographic imaging.

9. Subject is under 18 years of age.

10. Subject's anatomy limits ability to focus on or deliver Break Wave to the target stone (e.g. viable acoustic window).

11. Subject has a calcified abdominal aortic aneurysm or calcified renal artery aneurysms.

12. Subject has a solitary kidney.

13. Subject has a comorbidity risk(s) which, at the discretion of the physician, would make the subject a poor candidate for the Break Wave procedure, such as anatomical anomalies that may not be conducive to adequate stone fragment passage.

14. Subject is unable to read or comprehend the consent form.

Related Conditions & MeSH terms

• Calculi
• Kidney Calculi
• Kidney Stone
• Nephrolithiasis
• Renal Calculi
• Urinary Calculi
• Urolithiasis

Intervention

Device:
• Break Wave extracorporeal lithotripsy
The Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an ultrasound imaging system and a therapy probe driven by a high voltage generator. The probe will be placed on the patient's skin, the stone located via diagnostic ultrasound and up to 30 minutes of therapy will be delivered to the stone. The therapy probe accommodates coaxial alignment of an ultrasound imaging probe for treatment guidance.

Locations

Country	Name	City	State
Canada	University of Alberta	Edmonton	Alberta
Canada	St. Michael's Hospital, University of Toronto	Toronto	Ontario
Canada	University of British Columbia	Vancouver	British Columbia
United States	Lehigh Valley Health Network	Allentown	Pennsylvania
United States	Northwestern Medicine	Chicago	Illinois
United States	Vanderbilt University	Nashville	Tennessee
United States	University of California- San Diego	San Diego	California
United States	University of California - San Francisco	San Francisco	California
United States	Kaiser Permanente	Santa Clara	California
United States	University of Washington	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
SonoMotion

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Effectiveness Endpoint	Proportion of subjects with a radiographic assessment of the target stone demonstrating either (i) stone free status (zero fragments) or (ii) the presence of only stone fragments small enough to pass spontaneously (= 4 mm).	10 +/- 2 weeks post final Break Wave procedure
Primary	Primary Safety Endpoint	Occurrence of device and procedure related clinically significant or symptomatic hematoma (perirenal/intrarenal), urinary tract sepsis, or serious cardiac arrhythmia	During procedure and through 90 days post-procedure
Secondary	Secondary safety endpoint	Occurrence of all device and procedure related adverse events (AEs), including serious adverse events (SAEs), and Unanticipated Adverse Device Effects (UADEs)	During procedure and through 90 days post-procedure